CTLA4 and neoplasm: As expected, a higher PSMC5 level was significantly linked to expression of CD274 (PD-L1), CTLA-4, and IDO1 in CRC tumor cells (Figure 6H and Supplementary Figure 3A), indicating a potential role of inhibiting PSMC5 in immune checkpoint blockade (ICB) therapy.